De Novo device
ShortCut
Pi-Cardia, Ltd. · Percutaneous Catheter For Cutting Or Splitting Heart Valve Leaflets Concomitant To Transcatheter Valve Procedures (SCZ, Class II) · First FDA decision Sep 27, 2024, newest Sep 27, 2024Aortic stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
3
Naming "ShortCut"
MAUDE reports
0
Brand "ShortCut", since 2015
PubMed studies
2,318
Mentioning "ShortCut"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ShortCut
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Tricuspid Valve Replacement (TTVR)National analysisReview closedCAG-00467NUpdated Sep 24, 2026
- Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve RegurgitationNational analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438RUpdated Sep 23, 2026
- Transcatheter Mitral Valve Repair (TMVR)National analysisReview closedCAG-00438NUpdated Sep 23, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National analysisReview closedCAG-00468NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "ShortCut", any status and sponsor, newest update first.
Pi-cardiaNot on our public-company list
NCT06211296 · 8 participants · Start Jul 3, 2024 · Primary completion May 12, 2025
Device: Shortcut · For: Valve-in-valve Procedures; Aortic Stenosis; Coronary; Obstruction
Sites: Thousand Oaks, California; Morristown, New Jersey; New York, New York · 4 sites in all
- The ShortCut Post-Market StudyNot yet recruiting
Pi-cardiaNot on our public-company list
NCT07631988 · 150 participants (planned) · Start Jun 2026 · Primary completion Jul 2027
Device: Transfemoral catheter designed to split the bioprosthetic aortic valve leaflets prior to TAVR · For: Aortic Stenosis Treated With TAVI
- The ShortCut™ Study ProtocolCompleted
Pi-cardiaNot on our public-company list
NCT04952909 · 60 participants · Start Jan 21, 2022 · Primary completion Sep 30, 2023
Device: ShortCut™ · For: Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 23 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ShortCut", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SCZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ShortCut"[tiab]. The summary above synthesizes these.
- Shortcut to finite-time memory erasure.
Li G, Dong H · Phys Rev E · 2024
- Is There a Shortcut to Leaflet Splitting?
Rogers T · JACC Cardiovasc Interv · 2023Editorial, Comment
- LDLs take a shortcut to mitochondria.
Shinjo S, Scorrano L · Nat Cell Biol · 2023
- Modified Sympathectomy: Shortcut by Cutting Short.
Assis FR, Tandri H · JACC Clin Electrophysiol · 2021Editorial, Comment
- Intravenous sotalol-A shortcut to success?
Field ME · J Cardiovasc Electrophysiol · 2022Editorial, Comment
- Rectify ViT Shortcut Learning by Visual Saliency.
Ma C, Zhao L, Chen Y, et al. · IEEE Trans Neural Netw Learn Syst · 2024Research Support, Non-U.S. Gov't
- Shortcut Learning: Reduced But Not Resolved.
Selby IA, Roberts M, Breger A, et al. · Radiology · 2023Letter
- Editorial overview: Epigenetic inheritance: A shortcut to environmental adaptation?
Koseki H, Sharif J · Curr Opin Genet Dev · 2023Editorial
- Shortcut to death.
Schattenberg JM, Schuchmann M · Hepatology · 2009Comment
- Nature's Shortcut to Protein Folding.
Bergasa-Caceres F, Haas E, Rabitz HA · J Phys Chem B · 2019Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- Oncogenes and proto-oncogenes.
Bishop JM · Hosp Pract (Off Ed) · 1983
- A Shortcut to Activity-Dependent Transcription.
Sharma N, Gabel HW, Greenberg ME · Cell · 2015Comment
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.